Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    SONCHIMIO
Previous Study | Return to List | Next Study

Targeted Delivery of Chemotherapy With Ultrasound and Microbublles (SONCHIMIO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03458975
Recruitment Status : Recruiting
First Posted : March 8, 2018
Last Update Posted : April 8, 2020
Sponsor:
Information provided by (Responsible Party):
University Hospital, Tours

Brief Summary:

The oscillations of ultrasound (US) contrast agent microbubbles under their activation by US waves engender a modulation of the permeability of biological barriers amplifying hence the extravasation of drugs and/or fluorescent markers through a process known as sonoporation. In such a way, the bioavailability of the therapeutic agent is augmented only in the area where US waves are focused. The objective now is to translate this therapeutic approach to the clinic by performing a feasibility study with the development of a therapy regime optimized for hepatic metastases of colorectal cancer.

In order to demonstrate the clinical feasibility of the therapeutic approach based on ultrasound and microbubbles, we will focus on patients with liver metastases of colorectal cancer treated with monoclonal antibodies in combination with chemotherapy.


Condition or disease Intervention/treatment Phase
Colorectal Cancer Hepatic Metastases Radiation: MRI Radiation: Perfusion CT scan Other: Contrast enhanced ultrasound Drug: Sonoporation Phase 2

Detailed Description:

Despite the increasing number of active molecules and the availability of news targeted therapies for cancer, therapeutic achievements remain modest for a number of tumor types. One of the major obstacles is inherent to the absence of specific delivery in the tumor tissue.

We have demonstrated recently that the oscillations of ultrasound (US) contrast agent microbubbles under their activation by US waves engender a modulation of the permeability of biological barriers amplifying hence the extravasation of drugs and/or fluorescent markers through a process known as sonoporation. In such a way, the bioavailability of the therapeutic agent is augmented only in the area where US waves are focused. The objective now is to translate this therapeutic approach to the clinic by performing a feasibility study with the development of a therapy regime optimized for hepatic metastases of colorectal cancer.

In order to demonstrate the clinical feasibility of the therapeutic approach based on ultrasound and microbubbles, we will focus on patients with liver metastases of colorectal cancer treated with monoclonal antibodies in combination with chemotherapy.

The work aims into evaluating the therapeutic efficacy of the proposed approach on a number of selected patients. We will follow the usual treatment schemes and we will apply imaging protocols to visualize tumor progression.

This technique of optimization of the intratumoral availability of anticancer drugs and based on sonoporation will improve the efficacy and safety of systemic chemotherapy by providing increased tumor uptake relative to normal tissue. This technique provides an ideal and easy strategy to optimize intratumoral drug delivery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Targeted Delivery of Chemotherapy With Ultrasound and Microbubbles
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ultrasound

Arm Intervention/treatment
Active Comparator: Selected liver metastases of the patient
Liver metastases randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy
Radiation: MRI
Magnetic Resonance Imaging

Radiation: Perfusion CT scan
Perfusion Computerized tomography scan

Other: Contrast enhanced ultrasound
Contrast enhanced ultrasound

Drug: Sonoporation
Gaseous microbubbles (Sonovue) combinated with Ultrasounds

Placebo Comparator: Not-selected liver metastases of the patient
Liver metatstases not randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy like the active comparator arm
Radiation: MRI
Magnetic Resonance Imaging

Radiation: Perfusion CT scan
Perfusion Computerized tomography scan

Other: Contrast enhanced ultrasound
Contrast enhanced ultrasound




Primary Outcome Measures :
  1. Objective response for liver metastases [ Time Frame: 2 months ]
    Objective response for liver metastases with spiral CT scan and defined as decrease of at least 30% in the longer diameter of each selected liver metastases


Secondary Outcome Measures :
  1. Safety [ Time Frame: Day 3, Day 17, Day 32, Day 47 ]
    Safety based on National Cancer Institute (NCI), Common Terminology Criteria for Adverse events (CTCAE)

  2. Tolerance [ Time Frame: Day 3, Day 17, Day 32, Day 47 ]
    Tolerance based on National Cancer Institute (NCI), Common Terminology Criteria for Adverse events (CTCAE)

  3. Maximum percent reduction in tumor density on CT scan [ Time Frame: 2 months ]
    Maximum percent reduction in tumor density (Hounsfield units) from baseline

  4. Maximum percent reduction in tumor density on MRI [ Time Frame: 2 months ]
    Maximum percent reduction in tumor density from baseline

  5. Assessment of tumor vascularity by Perfusion CT scan [ Time Frame: 2 months ]
    Assessment of tumor vascularity with Perfusion CT scan

  6. Assessment of tumor vascularity by MRI [ Time Frame: 2 months ]
    Assessment of tumor vascularity with MRI

  7. Assessment of tumor vascularity by Dynamic Contrast-Enhanced US (DCE-US) [ Time Frame: 2 months ]
    Assessment of tumor vascularity with Dynamic Contrast-Enhanced US (DCE-US)

  8. Dosage of antibody anti-VEGF or anti-EGFR [ Time Frame: Day1, Day 3, Day 15, Day 17, Day 32, Day 45 ]
    Measures of serum concentration of antibody anti-VEGF or anti-EGFR

  9. Dosage of antibody anti-VEGF or anti-EGFR by ELISA test [ Time Frame: Day1, Day 3, Day 15, Day 17, Day 32, Day 45 ]
    Pharmacokinetic of antibody anti-VEGF or anti-EGFR

  10. Dosage of cytokines [ Time Frame: Day1, Day 3, Day 15, Day 17, Day 32, Day 45 ]
    Dosage of cytokines



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patient with liver metastases from colorectal cancer; patient with minimum two liver metastases which satisfy all the following criteria: diameter between 10 and 35 mm; arterially enhancing liver metastases detected with contrast enhanced ultrasound (CEUS); measurable liver metastases with CT-scan (Acceptability of a patient with more than 4 metastases or a patient with an odd number of metastases ≥ 2).
  • age ≥ 18 years;
  • ECOG/OMS 0-1;
  • life expectancy of at least 12 weeks;
  • adequate bone marrow, liver and kidney function;
  • written informed consent obtained from subject;
  • subjects covered by or having the rights to social security;
  • bi-weekly chemotherapy regimen
  • neo-adjuvant standard chemotherapy or palliative standard chemotherapy (first or second metastatic line) following the recommendations in force (national thesaurus of digestive oncology - colorectal cancer chapter: Phelip JM, Benhaim L, Bouché O, Christou N, Desolneux G, Dupré A, Léonard D, Michel P, Penna C, Rousseaux B, Tougeron D, Tournigand C. "Cancer colorectal métastatique". Thésaurus National de Cancérologie Digestive, Janvier 2019, http://www.tncd.org).

Exclusion Criteria:

  • Previous local treatment of selected liver metastases (radiofrequency, radioembolization, …);
  • Indication for local ablative therapy of selected liver metastasis (radiofrequency ablation or other validated hepatic-directed modality of treatment);
  • Previous malignancy other than colorectal adenocarcinoma within 3 years prior to the inclusion with the exception for curatively treated basal cell carcinoma of the skin and/or curatively resected in situ cervical or breast cancer;
  • Known contraindication to the injection of Sonovue®, of Gadolinium, of iodated contrast agent;
  • contraindication to MRI or perfusion CT scan;
  • Patient under legal protection;
  • Pregnant or lactating woman, or woman with ability to procreate and without contraception;
  • Inclusion in another therapeutic trial
  • Uracilemia greater than or equal to 150ng/mL (suggestive of a complete DPD deficiency).
  • Presence of any material with potential interaction with ultrasound beam (metal, etc.) or healing tissue, and which cannot be bypassed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03458975


Contacts
Layout table for location contacts
Contact: Ayache Bouakaz, MD +332 47 36 61 42 ayache.bouakaz@univ-tours.fr
Contact: Catherine Roussel +33247479789 roussel@med.univ-tours.fr

Locations
Layout table for location information
France
Service d'Hépatogastro-entérologie CHRU de TOURS Recruiting
Tours, France, 37044
Contact: LECOMTE Thierry, Pr    +33 2 47 47 59 00    thierry.lecomte@univ-tours.fr   
Contact: ROUSSEL Catherine, Mme    +33 2 47 47 97 89    roussel@med.univ-tours.fr   
Principal Investigator: LECOMTE Thierry, Pr         
Sponsors and Collaborators
University Hospital, Tours
Layout table for additonal information
Responsible Party: University Hospital, Tours
ClinicalTrials.gov Identifier: NCT03458975    
Other Study ID Numbers: PRTK15-TL/SONCHIMIO
First Posted: March 8, 2018    Key Record Dates
Last Update Posted: April 8, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Tours:
microbubbles
sonoporation
hepatic metastases of colorectal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes